"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial" by Paresh Dandona

Selected Works of Samer Nakhle, MD, FACE

Article

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial

The Lancet Diabetes & Endocrinology (2017)

Paresh Dandona, University at Buffalo
Chantal Mathieu, Katholieke Universiteit Leuven
Moshe Phillip, Tel Aviv University
Lars Hansen, Bristol-Myers Squibb
Steven C Griffen, JDRF
Diethelm Tschöpe, Ruhr University Bochum
Fredrik Thorén, AstraZeneca
John Xu, AstraZeneca
Anna Maria Langkilde, AstraZeneca
Joseph Proietto
Stephen Stranks
Roger Chen
David O'Neal
Alexia Pape
Mark Forbes
Claire Morbey
Anton Luger
Ursula Hanusch
Christoph Schnack
Evelyn Fliesser-Goerzer
Bertram Hoelzl
Christoph Ebenbichler
Rudolf Prager
Luc Van Gaal
Chris Vercammen
Andre Scheen, University of Liège
Francis Duyck
Frank Nobels
Johannes Ruige
Naresh Aggarwal
Vincent Woo
Bruno St-Pierre
Richard Dumas
Irene Hramiak
Thomas Elliott
Troels Krarup Hansen
Jan Erik Henriksen
Jeppe Gram
Aina Lihn
Jens Bruun
Juha Saltevo
Jyrki Taurio
Jorma Strand
Timo Valle
Sakari Nieminen
Kirsi Pietilainen
Bruno Guerci
Samy Hadjadj
Bertrand Cariou

Link

Disciplines

Publication Date

November 1, 2017

DOI

10.1016/S2213-8587(17)30308-X

Citation Information

Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, et al.. "Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial" The Lancet Diabetes & Endocrinology Vol. 5 Iss. 11 (2017) p. 864 - 876
Available at: http://works.bepress.com/samer-nakhle/18/